CRISPR Therapeutics CEO Kulkarni Samarth Sells 13,081 Shares at $58.15/Share.

CRISPR Therapeutics AG (CRSP) has announced that its Director and Chief Executive Officer, Samarth Kulkarni, has executed a transaction on August 18, 2023, wherein he sold 13,081 shares at a price of $58.15 per share.

Title: CRISPR Therapeutics AG: CEO Samarth Kulkarni Executes Share Sale

July 2, 2025 - CRISPR Therapeutics AG (CRSP) has seen significant activity in its shareholder transactions. On August 18, 2023, the company's Director and Chief Executive Officer, Samarth Kulkarni, sold 13,081 shares of the company's stock at a price of $58.15 per share. This transaction represents a strategic move by the executive, potentially aligning with the company's broader financial objectives.

The sale of shares by Kulkarni follows a period of increased institutional investment in CRISPR Therapeutics. During the first quarter of 2025, EverSource Wealth Advisors LLC boosted its holdings by 49,248.8%, acquiring an additional 84,708 shares and holding approximately 0.10% of CRISPR Therapeutics worth $2,888,000 [1]. This substantial increase in institutional investment underscores the growing confidence in CRISPR Therapeutics' potential.

In addition to EverSource Wealth Advisors, other institutional investors have also shown interest in CRISPR Therapeutics. Wood Tarver Financial Group LLC acquired a new stake worth approximately $30,000 in the fourth quarter of 2024. Costello Asset Management INC, Ameriflex Group Inc., NBC Securities Inc., and GF Fund Management CO. LTD. also made notable investments in the company's stock [1].

The company's stock has seen a trading range of $30.04 to $71.13 over the past year, with a current market cap of $5.43 billion and a P/E ratio of -11.00. CRISPR Therapeutics' stock has been the subject of various analyst reports, with mixed ratings and price targets. Chardan Capital and Piper Sandler have given the stock a "buy" rating, while Goldman Sachs and RBC have set more conservative price targets [1].

CRISPR Therapeutics' recent earnings report showed a 72.5% increase in quarterly revenue compared to the same period last year. However, the company reported a negative return on equity of 20.05% and a negative net margin of 1,229.43%. Despite these financial metrics, the company's gene-editing technology platform continues to attract significant interest from investors and analysts alike.

As CRISPR Therapeutics navigates its strategic path, the recent sale of shares by CEO Samarth Kulkarni adds another layer to the company's financial landscape. While the transaction may signal a shift in executive holdings, it is important to monitor the company's ongoing developments and financial performance for a comprehensive understanding of its future prospects.

References:
[1] https://www.marketbeat.com/instant-alerts/filing-eversource-wealth-advisors-llc-buys-84708-shares-of-crispr-therapeutics-ag-nasdaqcrsp-2025-08-16/